Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas

被引:26
作者
Alama, A
Barbieri, F
Favre, A
Cagnoli, M
Noviello, E
Pedulla, F
Viale, M
Foglia, G
Ragni, N
机构
[1] IST NAZL RIC CANC,DEPT CHEM CARCINOGENESIS,I-16132 GENOA,ITALY
[2] IST NAZL RIC CANC,DEPT PHARMACOTOXICOL,I-16132 GENOA,ITALY
[3] UNIV GENOA,DEPT HUMAN ANAT,I-16132 GENOA,ITALY
[4] UNIV GENOA,DEPT OBSTET & GYNECOL,I-16132 GENOA,ITALY
关键词
D O I
10.1006/gyno.1996.0194
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Three human cancer cell lines (OC 314, OC 315, and OC 316) were newly established in permanent culture from the ascites of patients with serous adenocarcinoma of the ovary. OC 314 was derived from an untreated tumor presenting with ascites at diagnosis; OC 315 was isolated from a neoplasm progressing after cisplatin-containing regimen; and OC 316 was collected from a patient with pleural metastasis at diagnosis, resistant to different chemotherapeutic treatments including Taxol. These cell lines were repetitively subcultured once to twice a week through 75-80 passage generations. Tumor cells grew as monolayers and displayed epithelial-like morphology, consistent with a feature of adenocarcinoma, which was then confirmed by the expressions of cytokeratins and vimentin. The cell Lines proved highly tumorigenic when transplanted into nude mice, both subcutaneously and intraperitoneally, In addition, the mice inoculated viith subcutaneous OC 316 developed extremely aggressive tumor, also invading the peritoneum, which correlated with the malignant behavior of the original tumor, Drug sensitivity, evaluated by the MTT Essay, showed that the three cell lines expressed similar sensitivity to doxorubicin. Responses to cisplatin essentially reported low sensitivity of OC 314 and OC 315 and resistance of OC 316, thus reflecting the original sensitivity at the clinical level. (C) 1996 Academic Press, Inc.
引用
收藏
页码:82 / 88
页数:7
相关论文
共 19 条
[1]  
BUICK RN, 1985, CANCER RES, V45, P3668
[2]   MEDICAL PROGRESS - CANCER OF THE OVARY [J].
CANNISTRA, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (21) :1550-1559
[3]   IMMUNOHISTOCHEMICAL LOCALIZATION OF A NOVEL BETA(1) INTEGRIN IN NORMAL AND PATHOLOGICAL SQUAMOUS EPITHELIA [J].
CERRI, A ;
FAVRE, A ;
GIUNTA, M ;
CORTE, G ;
GROSSI, CE ;
BERTI, E .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (02) :247-252
[4]   DNA INDEX OF OVARIAN CARCINOMAS FROM 56 PATIENTS - INVIVO INVITRO STUDIES [J].
ERBA, E ;
VAGHI, M ;
PEPE, S ;
AMATO, G ;
BISTOLFI, M ;
UBEZIO, P ;
MANGIONI, C ;
LANDONI, F ;
MORASCA, L .
BRITISH JOURNAL OF CANCER, 1985, 52 (04) :565-573
[5]   FLOW CYTOMETRIC ANALYSIS OF DNA CONTENT IN HUMAN OVARIAN CANCERS [J].
ERBA, E ;
UBEZIO, P ;
PEPE, S ;
VAGHI, M ;
MARSONI, S ;
TORRI, W ;
MANGIONI, C ;
LANDONI, F ;
DINCALCI, M .
BRITISH JOURNAL OF CANCER, 1989, 60 (01) :45-50
[6]   A NOVEL INTEGRIN INVOLVED IN THYMOCYTE THYMIC EPITHELIAL-CELL INTERACTIONS [J].
GIUNTA, M ;
FAVRE, A ;
RAMARLI, D ;
GROSSI, CE ;
CORTE, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (06) :1537-1548
[7]  
GODWIN AK, 1993, CANCER-AM CANCER SOC, V71, P530
[8]   ESTABLISHMENT AND CHARACTERIZATION OF 3 NEW HUMAN OVARIAN-CARCINOMA CELL-LINES AND INITIAL EVALUATION OF THEIR POTENTIAL IN EXPERIMENTAL CHEMOTHERAPY STUDIES [J].
HILL, BT ;
WHELAN, RDH ;
GIBBY, EM ;
SHEER, D ;
HOSKING, LK ;
SHELLARD, SA ;
RUPNIAK, HT .
INTERNATIONAL JOURNAL OF CANCER, 1987, 39 (02) :219-225
[9]   CHEMOTHERAPY FOR OVARIAN-CANCER [J].
KAYE, SB .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (04) :632-635
[10]  
LANGDON SP, 1988, CANCER RES, V48, P6166